Dr. Weijun Bai 白维君
Chief Physician
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and comprehensive treatment for lung cancer, breast cancer, malignant lymphoma, and digestive tract malignancies. Management of tumor emergencies including brain and bone metastases, superior vena cava syndrome, and malignant effusions.
Dr. Bai graduated from Jinzhou Medical College in 1985 and earned a master’s degree in oncology from China Medical University in 2001. Promoted to Chief Physician in 2003, Dr. Bai completed clinical training in Japan. Since graduation, Dr. Bai has specialized in medical oncology, focusing on chemotherapy, targeted therapy, and managing complications such as myelosuppression.
Professional roles
- Vice Chair, Chemotherapy Professional Committee, Liaoning Anti-Cancer Association
- Standing Committee Member, Oncology Professional Committee, Liaoning Association of Integrative Traditional Chinese and Western Medicine
- Member, Fourth Sarcoma Professional Committee, Liaoning Anti-Cancer Association
- Member, Respiratory Disease Branch, Liaoning Medical Association
Name order: in Chinese the family name comes first (Bai Weijun). Papers usually list the name as Weijun Bai or Bai W.
Selected publications
6 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Bioengineered, 2022 (senior author): Lemur tyrosine kinase 2 silencing inhibits the proliferation of gastric cancer cells by regulating GSK-3β phosphorylation and β-catenin nuclear translocation. PubMed 34719320
- Pathol Res Pract, 2019 (senior author): FBXL3 is regulated by miRNA-4735-3p and suppresses cell proliferation and migration in non-small cell lung cancer. PubMed 30594330
- Cancer Chemother Pharmacol, 2016 (senior author): Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin. PubMed 27473325
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion